Cefepime Hydrochloride for Injection Articles
Elan 1st-qtr net loss widens 20% to $102.6M
27 April 2009
Tysabri sales improve Elan's 2nd-qtr loss 49%
4 August 2008
Elan's 2007 loss up 51% on charges
25 February 2008
FDA issues early warnings on Elan's Maxipime
26 November 2007
Elan sees 3rd-qtr loss narrow, sales rise 43%
12 November 2007
Elan's 2nd-qtr 2007 loss deepens 56%
6 August 2007
Elan's 4th-qtr loss down 55%
5 March 2007
Elan's 3rd-quarter 2006 loss widens 74%
6 November 2006
Tysabri narrows Elan's 2nd-qtr losses 37%
7 August 2006
Elan's losses narrow; sees return to profit
15 May 2006
Elan posts $117.6M 2nd-qtr net loss
9 August 2004
Elan's 1st-qtr net loss plummets 52%
24 May 2004
Elan reports 34% drop in 2003 turnover
23 February 2004
Bristol-Myers Squibb's Maxipime in Japan
11 March 2002
Strong earnings growth for Ireland's Elan on healthy US sales
11 February 2002
Elan full-year 2000 sales top $1.50 billion
29 January 2001
Elan Corp set to acquire Dura Pharmaceuticals in $1.8 billion deal
11 September 2000
FDA approves Dura/BMS Maxipime for pediatric use
4 February 1999
B-MS' Maxipime; New Indication
12 June 1997
B-MS Gains Rights For Eisai Antifungal
23 December 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
B-MS/Meiji Seika Kaisha: Maxipime
18 September 1995
Bristol-Myers research operations
31 July 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
CAPOTEN APPROVED FOR DIABETES
7 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
Showing 1-37 of 37 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
